Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsOct 20, 2026, 10:03 PM ETvTv Therapeutics Inc. (VTVT) StockSA Transcripts162.52K FollowersvTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program October 20, 2026 2:30 PM EDTCompany ParticipantsPaul Sekhri - CEO, President & Chairman of the BoardMartin Lafontaine - Chief Commercial OfficerKlara KleinThomas Strack - Chief Medical OfficerConference Call ParticipantsSchafer BoederAlisa WeilersteinRitu Baral - TD Cowen, Research DivisionKambiz Yazdi - BTIG, LLC, Research DivisionMichael DiFiore - Evercore ISI Institutional Equities, Research DivisionAdam Walsh - ROTH Capital Partners, LLC, Research DivisionPresentationOperatorGood afternoon, everyone, and welcome to the vTv Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the vTv website following the conclusion of the event.I'd now like to turn the call over to Paul Sekhri, Chairman, President and CEO at vTv Therapeutics. Please go ahead, Paul.Paul SekhriCEO, President & Chairman of the BoardGood afternoon, everyone, and welcome. I'm Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. And on behalf of the entire team, thank you for joining us today for our KOL event on hypoglycemia in type 1 diabetes and the cadisegliatin Phase III program.Next slide, please. Before we begin, I'd like to remind you that today's presentation and accompanying remarks may include forward-looking statements about vTv's plans, products, operations and other matters as reflected in this slide. Also today's guest speakers are independent clinicians and advocates who have generously agreed to share their time and expertise. The views they express are their own opinions and do not necessarily reflect the views of vTv Therapeutics.Next slide, please. Today's agenda focuses on the burden of hypoglycemia and type 1 diabetes. Despite advances in diabetes management technology, hypoglycemia remains a persistent burden, one that extends beyond individual episodes to daily vigilance and fearRead more current VTVT analysis and newsView all earnings call transcriptsCommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.